Bahram Valamehr insider trades: Fate Therapeutics (FATE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Bahram reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | FATE | ↓ Sell | 43,947 | $2.46 | $108K | Direct | Aug 5, 2026 (1d) |
| May 20, 2026 | FATE | ↓ Sell | 28,946 | $1.88 | $54K | Direct | May 21, 2026 (1d) |
| Jan 9, 2026 | FATE | ↓ Sell | 5,190 | $1.07 | $6K | Direct | Jan 12, 2026 (3d) |
| Aug 4, 2025 | FATE | ↓ Sell | 14,466 | $1.06 | $15K | Direct | Aug 5, 2025 (1d) |
| Jan 10, 2025 | FATE | ↓ Sell | 8,705 | $1.54 | $13K | Direct | Jan 13, 2025 (3d) |
| Jan 9, 2024 | FATE | ↓ Sell | 11,271 | $4.38 | $49K | Direct | Jan 10, 2024 (1d) |
| Jan 10, 2023 | FATE | ↓ Sell | 10,917 | $5.24 | $57K | Direct | Jan 11, 2023 (1d) |
| Jul 7, 2022 | FATE | ↓ Sell | 17,158 | $30.23 | $519K | Direct | Jul 8, 2022 (1d) |
| Jul 6, 2022 | FATE | ↓ Sell | 7,842 | $30.07 | $236K | Direct | Jul 7, 2022 (1d) |
| Mar 14, 2022 | FATE | ↓ Sell | 25,000 | $31.07 | $777K | Direct | Mar 15, 2022 (1d) |
| Jan 11, 2022 | FATE | ↓ Sell | 4,570 | $48.50 | $222K | Direct | Jan 13, 2022 (2d) |
| Jan 10, 2022 | FATE | ↓ Sell | 5,596 | $46.38 | $260K | Direct | Jan 12, 2022 (2d) |
| Dec 13, 2021 | FATE | ↓ Sell | 25,000 | $47.66 | $1.2M | Direct | Dec 14, 2021 (1d) |
| Sep 13, 2021 | FATE | ↓ Sell | 25,000 | $66.29 | $1.7M | Direct | Sep 14, 2021 (1d) |
| Jun 14, 2021 | FATE | ↓ Sell | 25,000 | $89.32 | $2.2M | Direct | Jun 16, 2021 (2d) |
| Mar 15, 2021 | FATE | ↓ Sell | 25,000 | $92.35 | $2.3M | Direct | Mar 16, 2021 (1d) |
| Jan 11, 2021 | FATE | ↓ Sell | 9,484 | $114.95 | $1.1M | Direct | Jan 12, 2021 (1d) |
| Dec 14, 2020 | FATE | ↓ Sell | 25,000 | $97.78 | $2.4M | Direct | Dec 15, 2020 (1d) |
| Sep 14, 2020 | FATE | ↓ Sell | 25,000 | $36.28 | $907K | Direct | Sep 16, 2020 (2d) |
| Jan 8, 2020 | FATE | ↓ Sell | 5,700 | $20.69 | $118K | Direct | Jan 10, 2020 (2d) |
| Oct 15, 2019 | FATE | ↓ Sell | 6,200 | $14.18 | $88K | Direct | Oct 16, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other FATE insiders
Open-market trades in the last 12 months
About Bahram Valamehr's insider trades
Bahram Valamehr is President and CEO at Fate Therapeutics (FATE). Since Oct 15, 2019, Bahram has reported no open-market purchases and 21 sales worth $14.4M on SEC Form 4. In the last 12 months: 3 sales ($168K).
Their filings also include option exercises (11 filings), grants and awards (10 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every FATE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.